Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18 years or older: A randomized, double-blind, placebo-controlled, phase 1/2 trial

BACKGROUND: We aimed to assess the safety and immunogenicity of an inactivated vaccine against COVID-19 in Chinese adults aged ≥18 years. METHODS: This is an ongoing randomized, double-blind, placebo-controlled, phase 1/2 clinical trial among healthy adults aged ≥18 years in Henan Province, China. P...

Descripción completa

Detalles Bibliográficos
Autores principales: Guo, Wanshen, Duan, Kai, Zhang, Yuntao, Yuan, Zhiming, Zhang, Yan-Bo, Wang, Zejun, Zhao, Dongyang, Zhang, Huajun, Xie, Zhiqiang, Li, Xinguo, Peng, Cheng, Zhang, Wei, Yang, Yunkai, Chen, Wei, Gao, Xiaoxiao, You, Wangyang, Wang, Xue-Wei, Shi, Zhengli, Wang, Yanxia, Yang, Xu-Qin, Zhang, Lianghao, Huang, Lili, Wang, Qian, Lu, Jia, Yang, Yong-Li, Guo, Jing, Zhou, Wei, Wan, Xin, Wu, Cong, Wang, Wenhui, Du, Jianhui, Nian, Xuanxuan, Li, Xing-Hang, Huang, Shihe, Shen, Shuo, Xia, Shengli, Pan, An, Yang, Xiaoming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Research paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8260504/
https://www.ncbi.nlm.nih.gov/pubmed/34250456
http://dx.doi.org/10.1016/j.eclinm.2021.101010

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8260504/
https://www.ncbi.nlm.nih.gov/pubmed/34250456
http://dx.doi.org/10.1016/j.eclinm.2021.101010

Ejemplares similares